Related Experiment Video
Updated: Jun 17, 2025
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
DNA Origami-Constructed Nanotapes for Sunitinib Adsorption and Inhibition of Renal Clear Carcinoma Cells
Lin Li1, Xuxiang Yao1, Pengyao Wei1
1Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Ningbo Cixi Institute of Biomedical Engineering, Ningbo Institute of Materials Technology and Engineering of Chinese Academy of Sciences, Ningbo 315300, P. R. China.
Abstract:
Sunitinib (SUN) is a first-line drug for the treatment of renal clear carcinoma cells by targeting receptor tyrosine kinases (RTK) on the cell membrane. However, the effective delivery of SUN to the cell membrane remains a significant challenge. In this study, we fabricated precisely structured DNA nanotapes with strong surface SUN adhesion, enabling RTK inhibition of renal clear carcinoma cells. In our design, the precisely assembled linear topological six-helical-bundle DNA origami serves as the framework, and positively charged chitosan is adsorbed onto the DNA origami surface, thereby forming DNA nanotapes. The SUN was efficiently loaded onto the surface of the DNA nanotapes by electrostatic interaction. We found that DNA nanotapes exhibit excellent stability in serum. Importantly, DNA nanotapes carrying SUN can achieve prolonged cell membrane retention and inhibit RTK, thereby enhancing cytotoxicity toward 786-0 cells. Taken together, this study provides a promising candidate platform for the efficient delivery of cell membrane receptor inhibitors in anticancer therapy.
Insights
Researchers developed DNA nanotapes to effectively deliver sunitinib (SUN) for renal clear cell carcinoma treatment. This novel platform enhances drug retention and targets receptor tyrosine kinases (RTK) for improved cancer therapy.
Area of Science:
- Biotechnology
- Nanotechnology
- Oncology
Background:
- Sunitinib (SUN) is a first-line treatment for renal clear cell carcinoma, targeting receptor tyrosine kinases (RTK).
- Effective delivery of SUN to cancer cell membranes remains a significant challenge.
- Novel drug delivery systems are needed to improve anticancer therapy efficacy.
Purpose of the Study:
- To fabricate DNA nanotapes for enhanced sunitinib (SUN) delivery.
- To enable targeted inhibition of receptor tyrosine kinases (RTK) on renal clear carcinoma cells.
- To evaluate the efficacy of SUN-loaded DNA nanotapes in vitro.
Main Methods:
- Fabrication of DNA nanotapes using DNA origami frameworks and chitosan.
- Loading of SUN onto DNA nanotapes via electrostatic interaction.
- Assessment of DNA nanotape stability in serum and their cytotoxicity against 786-0 cells.
Main Results:
- DNA nanotapes demonstrated strong surface adhesion for SUN.
- The fabricated nanotapes showed excellent stability in serum.
- SUN-loaded DNA nanotapes achieved prolonged cell membrane retention, inhibited RTK, and enhanced cytotoxicity toward 786-0 cells.
Conclusions:
- Precisely structured DNA nanotapes provide a promising platform for efficient drug delivery.
- This approach enables targeted inhibition of cell membrane receptor inhibitors in anticancer therapy.
- DNA nanotapes offer a novel strategy for enhancing sunitinib efficacy in renal clear cell carcinoma treatment.
